Cortendo
As of the edition of 20 October 2026, Cortendo runs 2 drugs, 2 of them marketed; it is on route A at 0 targets and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Glucagon | none listed | 2 |
| Levoketoconazole | Ends 2028 (exclusivity) | 4 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 4 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Cortendo needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Hormones: 3 trials led
- Nervous system: 2 trials led